NCT05804396撤回不适用
The SP-303 PERL Study - Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for Preventive Treatment of Migraine
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 入组人数
- 57
- 主要终点
- Mean change in Monthly Migraine Days (MMD).
研究概览
简要总结
The PERL Study will evaluate the safety and efficacy of a self-administered preventive treatment for migraine headache using combined occipital and trigeminal nerve stimulation (Relivion®).
This is a prospective, non-randomized, single arm, multi-center study designed to evaluate the use of Relivion® in reducing the frequency of headache days against a sham performance goal.
详细描述
The study will include the following study visits & phases:
- Visit 1 Screening
- Run-in (Baseline) Period - Daily migraine headache diary.
- Visit 2 Enrollment -Study enrollment, device and regimen training.
- Treatment Period- Relivion® migraine preventive treatment for 12 consecutive weeks. Patients will be required to fill in a daily migraine diary.
- Visit 3 Follow Up Visit.
- Visit 4 Follow Up Visit.
- Visit 5 End of study.
After completion of visit 5 the subject's participation will be over.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects 18 years of age and older.
- •Subject meets the ICHD-3 (2018) diagnostic criteria for either Episodic migraine (<15 headache (HA) days/month) or Chronic (at least 15 days of HA/month with at least 8 days/month migraine days (migraine with and without aura) for > 3 months).
- •Subject migraine age of onset <50 years of age.
- •History of 6 to 24 headache days on average per month for the 3 months preceding study enrolment (based on participant report).
- •Completed at least 21 out of 28 days in the eDiary during run-in period. Partially completed data for the run-in period will be adjusted to reflect an estimated number of days with the outcome of interest per 28-day interval by using the formula (28/x)*y, where x is the number of days with observed data per 28-day period and y is the number of observed days with the outcome of interest.
- •Subject reports 6-24 headache days per 28 days, confirmed by 28 days or adjusted 28 days baseline diary.
- •Subjects on prophylactic migraine treatment are permitted to remain on 1 medication with possible migraine-prophylactic effects if the dose has been stable for at least 3 months prior to the screening visit, and the dose is not expected to change during the course of the study.
- •Subject is willing to and capable of complying with the specified study requirements, provided written Informed Consent can complete the electronic diaries, and can be contacted by telephone.
排除标准
- •Initiating or changing the type, dosage, or frequency of any medications for other indications than migraine that are determined to potentially interfere with the study.
- •Failure on ≥2 well-conducted preventive treatments. A treatment failure (lack of efficacy) trial is characterized as a Level A or Level B evidence-based preventive treatment (medications or a MAB or preventive gepant) for migraine preventive trial taken for a minimum of 2 months, at a minimally adequate dose, that produced less than 50% improvement in MMD reduction). Failure to tolerate a preventive treatment does not constitute a preventive treatment failure.
- •History of other chronic headache conditions such as Chronic tension-type headache, Medication Overuse Headache, New Daily Persistent Headache, and Cluster Headache in the prior 6 months.
- •Use of opiates or barbiturates medications in the prior 3 months.
- •Received parenteral infusions for migraine within the previous 2 weeks.
- •Subject has known uncontrolled epilepsy.
- •History of neuro-interventional procedures such as nerve blocks (within the last month), Botulinum Toxin (within the last 3-months), neurosurgical interventions in the head or neck, or implanted/wearable neurostimulators, electronic devices in the head, cardiac pacemaker, surgical clips above the shoulder line or medical pumps, except for dental implants.
- •Current drug abuse or alcoholism.
- •Subjects participating in other clinical trials evaluating experimental treatments or procedures.
- •Skin lesion, scars, or inflammation in the region of the stimulating electrodes.
- •Personality or somatoform disorder.
- •Pregnancy or Lactation.
- •Women of reproductive age not using a reliable contraceptive method, as determined by the Investigator (NOTE: Females of childbearing potential must have a negative pregnancy test).
- •Documented history of cerebrovascular event.
- •Subject with a recent history of traumatic brain injury (TBI), defined as a disruption in the normal function of the brain that can be caused by a bump, blow, or jolt to the head, or penetrating head injury, within 3 months of study enrollment.
- •Subjects who demonstrate or have a history of any cognitive disorder or impairment, memory loss, dementia, confusion or delirium that, in the opinion of the Investigator, may compromise the integrity of the study data or impact the ability of the subject to comply with the study requirements.
- •Subject diagnosed with other chronic pain disorder which in the opinion of the Investigator may compromise the integrity of the study data or impact the ability of the subject to comply with the study requirements.
- •The subject does not have the basic cognitive and motor skills needed to operate a smartphone.
- •Subject with head circumference smaller than 51 centimeters or head circumference larger than 60 centimeters.
结局指标
主要结局
Mean change in Monthly Migraine Days (MMD).
时间窗: 3 months
Mean change from baseline (M0) in Monthly Migraine Days (MMD) comparing with the last 28 treatment days (M3: weeks 9-12).
次要结局
- Mean change in monthly acute anti-migraine headache drug days.(3 months)
- Mean change total headache days.(3 months)
- Proportion of responder subjects(3 months)
研究者
相似试验
已完成
3 期
Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia ASevere Haemophilia ANCT02256917Octapharma58
尚未招募
不适用
PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line ChemotherapyBrain MetastasisBreast CancerNCT02448576wang shusen326
招募中
3 期
Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line ChemoradiotherapyLimited Stage Small Cell Lung CancerNCT04829708Shandong Cancer Hospital and Institute534
已完成
3 期
Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Nails Affected by PsoriasisNail PsoriasisNCT02606760Polichem S.A.378
已完成
3 期
A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)Plaque PsoriasisNCT02742441Therapeutics, Inc.409